The World Market for Therapeutic Proteins, 2005

The World Market for Therapeutic Proteins, 2005

The Therapeutic Proteins market is huge, selling drugs in 2003 worth almost
$37bn, and with a dramatic growth rate of a massive 19%. This is obviously a
highly lucrative and valuable market and visiongain predicts that this
market will grow to over $90bn by 2010. For any company thinking of entering
this market visiongain's: The World Market
for Therapeutic Proteins, 2005 is an essential buy.

It is likely that anyone entering this market will make significant profits.
However, not all therapeutic indications are the most profitable and
visiongain's: The World Market for Therapeutic Proteins, 2005 will show
specifically which medical areas to enter and why.
Other questions that will be answered within this report include:
Who are the main competitors and will their dominance continue to 2010?
Which areas are headed for high growth and why?
What are the principle drugs in the market and how will their revenue change
over time?
Which are the most important therapeutic areas to launch new products and
why?
Will the shortfall in manufacturing capacity dampen its growth?
Will the high cost of these drugs ever be reduced?
And how imminent is the threat from biogeneric competition?


All these questions and many others are answered visiongain's 230+ page
report: The World Market for Therapeutic Proteins, 2005
Therapeutic Proteins are used to treat a variety of diseases which accounts
for its very high revenues and alleviates the suffering of millions of
people, such diseases include:
Cancers
Heart attacks
Anaemia
Strokes
Diabetes
Cystic fibrosis
Haemophilia


WHY YOU MUST BUY THIS REPORT
With over 80 graphs and figures, plus 60 tables, this report represents a
key tool for companies wishing to enter into or expand in the therapeutic
protein market. You will be left with a clear idea of:
1. The challenges faced by the therapeutic protein market, and how these are
being overcome
2. The current and future market leaders in terms of brand, class, category
and company, covering the period 2003-2010
3. Therapeutic targets currently being developed in the field and who is
responsible for this development
4. The competition that companies will face during the forecast period from
current and pipeline products

If you want to be a success in the Therapeutic Proteins market then you
can't do without visiongain's The World Market for Therapeutic Proteins,
2005. This is an essential guide to acquiring the very high profits that are
to be found in this rapidly expanding marketplace. Don't miss out on this
highly lucrative market.


TABLE OF CONTENTS

1. Executive Summary

2. Introduction
2.1 What are Therapeutic Proteins?
2.2 What is the Market for Therapeutic Proteins and how will it Alter in the
Future?
2.3 Aims, Scope and Format of this Report

3. Unmet Needs and Key Issues Affecting the Therapeutic Protein Market
3.1 Drug Delivery Challenges
3.1.1 The Majority of Therapeutic Proteins Can Only be Administered
Parenterally
3.1.2 Pulmonary Delivery: A Viable Alternative to Injections
3.1.2.1 What is the Main Challenge in Pulmonary Delivery?
3.1.2.2 Are There any Problems with Bioavailability?
3.1.2.3 Does the Formulation of the Protein Affect its Delivery?
3.1.2.4 Syntonix are Developing Pulmonary Technology that does not Require
Deep-Lung Delivery
3.1.2.5 Does Pulmonary Drug Delivery Have a Future?
3.1.3 Nasal Delivery Enables Pulsed-Release Dosing, Which Aids Protein
Effectiveness
3.1.3.1 What Types of Nasal Drug Delivery Systems are in Development?
3.1.3.2 The ChiSys(tm) Nasal Delivery System
3.1.4 Oral Delivery: In Development by Altus
3.1.5 Microneedles for Transdermal Delivery of Vaccines
3.1.6 Are There Methods for Increasing the Half-Life of a Protein?
3.1.6.1 Polymeric Delivery Ensures Proteins Remain Active for Longer
3.1.6.2 Polymer-Protein Conjugation
3.1.7 Can Advances in Protein Drug Delivery Result in Drugs for Treatment of
CNS Disorders?
3.2 Manufacturing Capacity Shortfall
3.2.1 Why is There a Shortfall in Manufacturing Capacity for Therapeutic
Proteins?
3.2.1.1 Make Vs. Buy in the 1980s
3.2.1.2 CMO Manufacturing Capacity was Adequate for the Supply of Clinical
Materials Only
3.2.1.3 Late-Stage Products have absorbed CMO Clinical Manufacturing
Capacity
3.2.2 How is the Manufacturing Capacity Shortfall Being Overcome?
3.2.3 Does The Future for Therapeutic Protein Manufacturing Lie with
Transgenics?
3.3 The Cost of Therapeutic Proteins
3.3.1 The Top Ten Therapeutic Proteins Each Cost at Least $10K Per Patient
Per Year
3.3.2 What Do the Most Costly of the Top Ten Therapeutic Proteins Have in
Common?
3.3.3 Yeast-Based Systems May Bring Down the Cost of Therapeutic Proteins in
the Future
3.4 Biogeneric Competition: A Real or Limited Threat?
3.4.1 How are Approval Pathways Limiting the Development of Biogenerics?
3.4.2 Will the Benefits of Biogenerics be as Great as Anticipated?
3.4.3 What About the High Cost of Market Entry?
3.4.4 What About Manufacturing Capacity Problems?
3.4.5 What Class of Therapeutic Protein is the Chief Target for Biogenerics?
3.4.6 How Imminent is the Threat from Biogeneric Competition?
3.5 Drivers and Restraints of the Therapeutic Protein Market

4. An Overview of the Global Therapeutic Proteins Market, 2003-2004
4.1 The Therapeutic Proteins Market Increased by Almost 20% in 2003, Gaining
Six New Products and Four Blockbusters
4.2 Four of the Six Newcomers are Monoclonal Antibodies
4.2.1 Pegasys is the Best-Selling Newcomer to the Therapeutic Protein, and
Global Pharma Market
4.2.2 Humira is the Best-Selling New Monoclonal Antibody on the Market
4.2.3 Fabrazyme Made $81m in Eight Months
4.2.4 Amevive Was Approved for Sale in Canada in 2004
4.2.5 Herceptin is Now Enjoying Success in Japan
4.2.6 Xolair: Sales of $170m Expected in its First Full Year on the Market
4.2.7 Newcomers will be Market Drivers in 2004 with a Triple-Digit Increase
in Sales
4.3 The Therapeutic Protein Market Contained 11 Blockbuster Products
4.4 The Top Three Therapeutic Proteins Sold Over $8bn in 2003 and Held a 23%
Market Share
4.4.1 Procrit/Eprex - The Number One Therapeutic Protein Struggles at the
Top
4.4.2 Epogen is the Second Best-Selling Therapeutic Protein
4.4.3 Intron A and Peg-Intron
4.5 Aranesp, Neulasta and Enbrel are the Most Successful Therapeutic
Proteins in Terms of Growth
4.5.1 Aranesp is the Fastest-Growing Therapeutic Protein
4.5.1.1 Head-to-Head Studies Show Aranesp Dosed Every Two Weeks is
Comparable to Epoetin Alfa Dosed Once a Week
4.5.1.2 Sales of Aranesp Will Top $2.3 Billion in 2004
4.5.2 Neulasta - Amgen's Neutropenia Superstar
4.5.3 Enbrel Completes a Hat Trick for Amgen as the Third Fastest-Growing
Therapeutic Protein on the Market
4.5.3.1 Enbrel Has a Number of New Indications
4.5.3.2 Side-Effects of Competitor Medications May Prove Advantageous for
Enbrel
4.6 The Intron A Family and Genotropin were the Least Successful Therapeutic
Proteins in Terms of Growth
4.7 The Leading Classes of Therapeutic Proteins are Erythropoietins,
Monoclonal Antibodies and Interferons
4.7.1 Erythropoietins Lead with a More-Than Quarter Share of the Market
4.7.2 The Monoclonal Antibody Class Contained More Products than Any Other
Class of Therapeutic Protein
4.7.3 Interferons Sold $5.5 Billion in 2003 but are Set for Huge Losses in
2004
4.8 Blood Modifiers, Multiple Sclerosis and Anti-Arthritic Drugs are the
Leading Therapeutic Categories for Therapeutic Proteins
4.8.1 Blood Modifiers Dominate Due to Erythropoietins
4.8.2 Multiple Sclerosis Drugs Hold on to Their Market Share
4.8.3 Anti-Arthritic Drugs are Third Best-Selling and Fastest-Growing
Therapeutic Category
4.9 Only Two Therapeutic Categories Saw Negative Growth in 2003
4.10 Amgen Dominates the Market with Almost $8 Billion in Sales
4.10.1 Who are Amgen?
4.10.2 All of Amgen's Therapeutic Proteins are Blockbusters.... And Other
Facts
4.11 Johnson and Johnson: The Second Most-Successful Company in the Market
is Losing its Grip
4.12 Roche are the Number Three in the Market with Drugs For a Variety of
Indications
4.13 Wyeth: One of the Fastest-Growing Companies with all Products
Experiencing Double-Digit Growth

5. The Market for Erythropoietins
5.1 What is Erythropoietin?
5.2 What are the Different Types of Erythropoietins on the Market and What
are they Worth?
5.3 Procrit/Eprex' Sales will Recover
5.4 Epogen - The Class Progenitor
5.5 Aranesp - The New EPO on the Block
5.6 NeoRecormon Will Be Unaffected by Patent Expiry
5.7 Epogin and Espo
5.8 The Erythropoietin Pipeline
5.8.1 Cera will Replace NeoRecormon as Roche's Leading Erythropoietin
5.8.2 Dynepo is Ready to be Marketed in the EU but Still Awaits FDA Approval
5.8.3 Roche Have Another Erythropoietin in Early-Stage Development
5.9 The Erythropoietin Class will be Worth Over $17bn by 2010

6. The Market for Monoclonal Antibodies
6.1 What are Monoclonal Antibodies?
6.2 What are the Problems Associated with Monoclonal Antibodies as
Therapeutic Agents?
6.3 What Monoclonal Antibodies are on the Market and what are they Worth?
6.4 What Types of Monoclonal Antibodies are There and What Conditions do
They Treat?
6.4.1 Murine
6.4.2 Chimeric Antibodies
6.4.3 Humanised Antibodies (CDR-Grafted)
6.4.4 Human Antibodies
6.4.5 Receptor-Antibody Fusion Protein
6.4.6 Chimeric Monoclonal Antibodies Dominate the Market
6.4.7 Monoclonal Antibodies Have Eight Main Indications, of Which Arthritis
is the Best Selling
6.4.8 Why do Arthritis Medications Dominate?
6.4.9 Non-Hodgkin's Lymphoma Drugs Come a Close Second to Arthritis
Medications
6.4.10 What is Non-Hodgkin's Lymphoma and how Prevalent is it?
6.5 Remicade is the Best-Selling Monoclonal Antibody
6.5.1 How Safe is Remicade?
6.5.2 Remicade Lacks Patent Protection and Market Exclusivity but Continues
to Grow
6.6 Genentech's Rituxan Leads the Way in Treatment for Non-Hodgkin's
Lymphoma
6.7 Herceptin is the Third Best Selling MAb on the Market
6.8 What are the Most Promising New MAbs on the Market?
6.8.1 Abbott's Humira is the First in its Class
6.8.2 Bexxar and Zevalin Represent Another New Class of MAbs
6.8.3 Avastin: An Important New Treatment for the Third Most Fatal Cancer in
the US
6.8.4 Erbitux will Enjoy Success, but not on the Same Scale as Avastin
6.9 The Monoclonal Antibody Late-Stage Pipeline
6.9.1 Tysabri Could Take a 50% Share of the Multiple Sclerosis Market
6.10 The Monoclonal Antibody Early-Stage Pipeline
6.11 Monoclonal Antibodies Will be Worth Over $26 Billion by 2010

7. The Market for Interferons
7.1 What is an Interferon?
7.2 What Diseases do Interferons Treat?
7.3 What Interferons are on the Top 400 Market and How Much are they Worth?
7.4 The Intron A Family versus Pegasys: Pegasys Looks Set for Victory
7.4.1 What is Pegasys and what makes it Different from Other Hepatitis
Treatments?
7.4.2 Pegasys Can Now Also Treat Hepatitis B
7.4.3 Pegasys will be the Market Leader by 2005
7.5 Who Will Win the War to Become the Top-Selling Multiple Sclerosis
Treatment?
7.5.1 Market-Leading Avonex will soon Succumb to Competitive Pressure from
Rebif
7.5.2 Betaseron will Remain a Best-Seller, But Growth will be Relatively
Flat
7.6 The Interferon Pipeline
7.6.1 Nastech Pharma Have a Nasal Interferon Available for Licensing
Box 7.1 Who are Nastech Pharmaceuticals?
7.6.2 Amarillo Biosciences are Developing an Oral Interferon for Hepatitis C
Box 7.2 Who are Amarillo Biosciences?
7.7 The Market for Interferons will be Worth over $12bn in 2010

8. The Market for Insulin
8.1 What is Insulin?
8.2 How Prevalent is Diabetes?
8.3 What Insulin Treatments are on the Market and What are They Worth?
8.4 Humulin Will Lose its Spot at the Top to Lilly's New and Improved
Humalog
8.5 Sanofi-Aventis' Lantus is Rising Fast to the Top of the Insulin Market
8.6 Recently-Approved Insulins: How Will They Perform?
8.6.1 Novo Nordisk Claims New Product Superior to Lantus
8.6.2 Apidra May Benefit from Lantus' Success
8.7 The Insulin Pipeline
8.7.1 Exubera will be the First Non-Injected Insulin on the Market
8.7.2 Novo Nordisk May Launch Their Inhaled Insulin by 2009
8.7.3 Generex Biotech Lead the Race to Market the First Oral Insulin
8.7.4 Will HIM2 be the First Insulin Pill on the Market?
8.8 Lantus will be the Top Selling Insulin in 2010, when the Market will be
Worth $9.5bn

9. The Market for Colony Stimulating Factor
9.1 What is Colony Stimulating Factor and What Diseases does it Treat?
9.2 What CSFs are Available and What is the Market Worth?
9.3 Neupogen: Amgen's Orphan Drug for the Treatment of Neutropenia
9.4 Amgen Has Released a New-Improved Form of Neupogen: Neulasta
9.5 Little Competition for Amgen in the Neutropenia Market
9.6 The CSF Pipeline
9.7 The CSF Market will be Worth Over $4.8bn by 2010

10. The Market for Other Classes of Therapeutic Protein
10.1 The Market for Blood Factors
10.1.1 What are Blood Factors and which ones Feature on the Therapeutic
Protein Market?
10.1.2 What is Haemophilia and how Prevalent is it?
10.1.3 NovoSeven is the Top Selling Haemophilia Drug, but not for Long
10.1.4 Kogenate: The Runner-Up to NovoSeven
10.1.5 Benefix: Wyeth's Breakthrough Haemophilia B Treatment
10.1.6 ReFacto: Wyeth's Breakthrough Haemophilia A Treatment
10.1.7 The Blood Factor Pipeline
10.1.8 By 2010 Blood Factors will be Worth in Excess of $2.5bn
10.2 The Market for Therapeutic Vaccines
10.2.1 The Market for Therapeutic Vaccines is Sparse
10.2.2 Why is the Market Experiencing Flat Growth?
10.2.3 The Therapeutic Vaccine Pipeline
10.2.4 Sales of Therapeutic Vaccines will Grow in Double-Digits in the
Forecast Period
10.3 The Market for Growth Hormones
10.3.1 What is Growth Hormone and What is the Market Worth?
10.3.2 What is Growth Failure and What Causes it?
10.3.3 Genotropin: Pfizer Under Investigation
10.3.4 Humatrope: Eli Lilly's Growth Hormone
10.3.5 Nutropin, Nutropin Depot and Protropin
10.3.6 The Hormone Market will Experience Flat Growth Between 2004 and 2010
10.4 The Market for Enzymes
10.4.1 What are Enzymes, what Diseases do they Treat and what is the Market
Worth?
10.4.2 What is in the Enzyme Pipeline?
10.4.3 All Enzymes on the Market will Enjoy Positive Growth Between 2004 and
2010
10.5 The Market for Enbrel
10.5.1 What is Enbrel and what is it Worth?
10.5.2 Who are Enbrel's Competitors on the Therapeutic Protein Market?
10.5.3 Enbrel will Grow with a CAGR of Almost 16% Between 2004 and 2010
10.6 The Market for Copaxone
10.6.1 What is Copaxone and What is it Worth?
10.6.2 New Indications for Copaxone are in the Pipeline
10.6.3 Who are Copaxone's Competitors on the Therapeutic Protein Market?
10.6.4 Sanofi-Aventis Will Overtake Teva in Sales of Copaxone

11. Forecast Summary for Therapeutic Proteins, to 2010
11.1 Aranesp Will be the Market Leader in 2010
11.2 The Market Leader Will Hold A Smaller Market Share in 2010 than in 2003
11.3 Monoclonal Antibodies will Become the Leading Class of Therapeutic
Protein
11.4 Monoclonal Antibodies and Insulin will be the Fastest Growing Classes
11.5 Blood Modifiers will Remain the Top Therapeutic Category
11.6 Amgen will Remain the Market Leaders and Retain Their Market Share
11.7 The Therapeutic Protein Market will Total Over $90bn by 2010

12. Conclusion: The Market will Continue its Double-Digit Growth for the
Foreseeable Future
LIST OF GRAPHS, TABLES AND FIGURES
Graphs
Graph 1.1 The Top 20 Therapeutic Proteins by Revenue ($m), 2003
Graph 3.1 Cost of Per Patient ($m) of the Top Ten Therapeutic Proteins, 2003
Graph 4.1 Revenues ($m) for Newcomers to the Therapeutic Protein Market,
2003-2004
Graph 4.2 Revenues ($m) for New Blockbusters on the Market, 2003
Graph 4.3 Revenues ($m) for Blockbuster Therapeutic Proteins, 2003
Graph 4.4 Global Procrit/Eprex Sales ($m), 2001-2004
Graph 4.5 Global Epogen Sales ($m), 2001-2004
Graph 4.6 Global Intron A Family Sales ($m), 2001-2004
Graph 4.7 Top Ten Winners and Losers in the Global Therapeutic Protein
Market by Growth Rate (%), 2003
Graph 4.8 Global Aranesp Sales ($m), 2001-2004
Graph 4.9 Global Neulasta Sales ($m), 2002-2004
Graph 4.10 Global Enbrel Sales ($m), 2001-2004
Graph 4.11 Global Sales ($m) of Therapeutic Proteins by Class, 2003
Graph 4.12 Class Winners and Losers in the Therapeutic Protein Market by
Growth Rate (%), 2003
Graph 4.13 Copaxone Sales ($m) by Company, 2001-2004
Graph 4.14 Market Shares (%) for Anti-Arthritic Therapeutic Proteins,
2003-2004
Graph 4.15 Winners and Losers in the Therapeutic Protein Market by Growth
Rate (%), according to Therapeutic Category, 2003
Graph 4.16 Top Ten Companies in the Therapeutic Protein Market by Revenue
($m), 2003
Graph 4.17 Amgen's Annual R&D Expenditure ($m), 1993-2003
Graph 4.18 Company Winners and Losers in the Therapeutic Protein Market by
Growth Rate (%), 2003
Graph 5.1 Forecast of Global Procrit/Eprex Sales ($m), 2004-2010
Graph 5.2 Forecast of Global Epogen Sales ($m), 2004-2010
Graph 5.3 Forecast of Global Aranesp Sales ($m), 2004-2010
Graph 5.4 Forecast of Global NeoRecormon Sales ($m), 2004-2010
Graph 5.5 Forecast of Global Epogin Sales ($m), 2004-2010
Graph 5.6 Forecast of Global Espo Sales ($m), 2004-2010
Graph 5.7 The Global Market ($m) for Erythropoietins, 2004 Versus 2010
Graph 5.8 The Global Market ($m) for Erythropoietins, 2010
Graph 5.9 CAGR (%) for the Global Erythropoietins Market, 2004-2010
Graph 5.10 Forecast for the Global Erythropoietins Market ($m), 2004-2010
Graph 6.1 Global Revenues ($m) for MAbs by Class, 2003
Graph 6.2 Global Revenues ($m) for MAbs by Indication, 2003
Graph 6.3 Global Sales ($m) of Remicade by Company, 2004-2010
Graph 6.4 Global Rituxan Sales ($m), 2004-2010
Graph 6.5 Global Herceptin Sales ($m) by Company, 2004-2010
Graph 6.6 Global Humira Sales ($m), 2004-2010
Graph 6.7 Global Zevalin Sales ($m), 2004-2010
Graph 6.8 Global Bexxar Sales ($m), 2004-2010
Graph 6.9 Global Avastin Sales ($m), 2004-2010
Graph 6.10 Global Erbitux Sales ($m), 2004-2010
Graph 6.11 Global Sales ($m) of Selected Monoclonal Antibodies, 2010
Graph 6.12 CAGRs (%) for Selected Monoclonal Antibodies, 2004-2010
Graph 6.13 Total Global Revenue ($bn) for the MAb Market, 2004-2010
Graph 7.1 Global Sales ($m) of the Intron A Family Versus Pegasys, 2004-2010
Graph 7.2 Global Intron A Family Sales ($m), 2004-2010
Graph 7.3 Global Sales ($m) of Interferons for Multiple Sclerosis, 2004-2010
Graph 7.4 Best-Selling Interferons ($m), 2010
Graph 7.5 CAGRs (%) for the Best-Selling Interferons, 2004-2010
Graph 7.6 Total Global Revenues ($bn) for the Interferon Market, 2004-2010
Graph 8.1 Global Humulin and Humalog Sales ($m), 2004-2010
Graph 8.2 Global Lantus Sales ($m), 2004-2010
Graph 8.3 Global Levemir Sales ($m), 2004-2010
Graph 8.4 Global Apidra Sales ($m), 2004-2010
Graph 8.5 Global Exubera Sales ($m), 2005-2010
Graph 8.6 Global Insulin Sales ($m), 2010
Graph 8.7 CAGRs (%) for Insulins, 2004-2010
Graph 8.8 Total Global Revenues for the Insulin Market ($m), 2004-2010
Graph 9.1 The Global CSF Market ($m), 2004-2010
Graph 10.1 Global Revenues ($m) for Blood Factor Brands 2004 Versus 2010
Graph 10.2 The Global Blood Factor Market ($m), 2004 Versus 2010
Graph 10.3 Global Revenue ($m) for Therapeutic Vaccines, 2004 and 2010
Graph 10.4 Global Revenue ($m) for Growth Hormones, 2004 Versus 2010
Graph 10.5 The Global Enzyme Market ($m), 2004 vs. 2010
Graph 10.6 Global Enbrel Revenue ($m) by Company, 2004 vs. 2010
Graph 10.7 Global Sales ($m) for Copaxone Versus Competitor Therapeutic
Proteins for MS, 2004-2010
Graph 11.1 Top Ten Therapeutic Proteins Globally by Revenue ($m), 2010
Graph 11.2 Revenue ($m) for Therapeutic Proteins by Class, 2010
Graph 11.3 CAGRs (%) for Classes of Therapeutic Protein, 2003-2010
Graph 11.4 Global Revenues ($m) for Therapeutic Proteins by Therapeutic
Category, 2010
Graph 11.5 Top Ten Companies by Revenue ($m) in the Therapeutic Protein
Market, 2010
Graph 12.1 Total Revenue ($m) for the Therapeutic Protein Market, 2003-2010
Tables
Table 1.1 Top 3 Classes, Therapeutic Categories and Indications for
Therapeutic Proteins by Revenue, 2003
Table 2.1 Examples of Diseases that Therapeutic Proteins Treat
Table 3.1 Methods of Administration (MoA) for the Top Ten Therapeutic
Proteins (2003)
Table 3.2 Features of the Top Ten Therapeutic Proteins (2003), Relevant to
Cost
Table 3.3 Barriers to Overcome and Entry Strategies to Compete Successfully
in the Biogenerics Market
Table 3.4 Manufacturing: Make or Buy?
Table 3.5 Drivers and Restraints of the Therapeutic Protein Market, 2005
Table 4.1 The Global Therapeutic Protein Market ($m), 2002-2003
Table 4.2 Top 20 Therapeutic Proteins by Revenue ($m), 2003
Table 4.3 Newcomers to the Global Therapeutic Protein Market, 2003
Table 4.4 Revenues ($m) for Blockbuster Therapeutic Proteins, 2003
Table 4.5 Revenue ($m) for Arthritis Medications in the Top 100, 2003
Table 4.6 Revenue ($m) for Classes of Therapeutic Protein, 2003
Table 4.7 Top Therapeutic Categories for Therapeutic Proteins by Revenue
($m), 2003
Table 4.8 Blood Modifying Therapeutic Proteins by Class and Revenue ($m),
2003
Table 4.9 Global Revenues ($m) for Multiple Sclerosis Therapeutic Proteins,
2003
Table 4.10 Global Revenues ($m) for Anti-Arthritic Therapeutic Proteins,
2003
Table 4.11 Revenues and Market Shares (%) for Anti-Arthritic Therapeutic
Proteins, 2003-2004
Table 4.12 Revenues ($m) for Hormonal Treatments on the Therapeutic Proteins
Market, 2003
Table 4.13 Amgen's Therapeutic Proteins by Global Revenues ($m), 2003
Table 4.14 Roche's Therapeutic Proteins by Global Revenues ($m), 2003
Table 4.15 Wyeth's Therapeutic Proteins by Global Revenues ($m), 2003
Table 5.1 Global Erythropoietin Revenue ($m), 2003
Table 5.2 The Erythropoietin Pipeline, 2005
Table 5.3 The Global Market ($m) for Erythropoietins, 2004-2010
Table 6.1 The Global MAb Market ($m), 2003
Table 6.2 Classes and Indications of MAbs on the Market, 2003
Table 6.3 Selected MAbs in Late-Stage Development, 2005
Table 6.4 Selected MAbs in Early-Stage Development, 2005
Table 6.5 Global Sales ($m) of Monoclonal Antibodies, 2004-2010
Table 7.1 Indications of Currently Marketed Interferons, 2005
Table 7.2 The Global Interferon Market ($m), 2003
Table 7.3 The Interferon Pipeline, 2005
Table 7.4 Global Interferon Revenues ($m), 2004-2010
Table 8.1 Insulin Treatments on the Top 400 Market, 2003
Table 8.2 Selected Products in the Insulin Pipeline, 2005
Table 8.3 Total Global Insulin Sales ($m), 2004-2010
Table 9.1 The Global CSF Market ($m), 2003
Table 9.2 The CSF Pipeline, 2005
Table 9.3 Value of the Global CSF Market ($m), 2004-2010
Table 10.1 The Global Blood Factors Market ($m), 2003
Table 10.2 The Blood Factor Pipeline, 2005
Table 10.3 Global Revenues ($m) for the Top-Selling Blood Factors, 2004 and
2010
Table 10.4 The Therapeutic Vaccine Pipeline, 2005
Table 10.5 Global Revenues ($m) for Therapeutic Vaccines 2004 Versus 2010
Table 10.6 The Global Market ($m) for Growth Hormones, 2003
Table 10.7 The Growth Hormone Pipeline, 2005
Table 10.8 Global Revenues ($m) for Growth Hormones, 2004 Versus 2010
Table 10.9 The Global Enzyme Market ($m), 2003
Table 10.10 The Enzyme Pipeline, 2005
Table 10.11 Global Revenue ($m) for Enzymes, 2004 vs. 2010
Table 10.12 Positions for Anti-Arthritic Therapeutic Proteins, 2003 and 2009
Table 10.13 Global Copaxone Sales ($m), 2004-2010
Table 11.1 Top Ten Therapeutic Proteins Globally by Revenue ($m), Including
Co- Marketing Splits, 2010
Table 11.2 Top Ten Therapeutic Proteins Globally by Revenue ($m), Excluding
Co-Marketing Splits, 2010
Table 11.3 Revenue ($m) for Therapeutic Proteins by Class, 2010
Table 11.4 CAGRs (%) for Classes of Therapeutic Protein, 2003-2010
Table 11.5 Global Revenues ($m) for Therapeutic Proteins by Therapeutic
Category, 2010
Table 11.6 Top Ten Companies in the Therapeutic Protein Market Globally by
Revenue ($m), 2010
Table 11.7 The Global Therapeutic Proteins Market ($m), 2010
Table 12.1 Therapeutic Proteins in the Pipeline with Non-Parenteral Methods
of Delivery, 2005
Figures
Figure 4.1 The Market Share (%) for All Blockbuster Therapeutic Proteins,
2003
Figure 4.2 Global Market Shares (%) for the Top-Selling Therapeutic
Proteins, 2003
Figure 4.3 Global Market Shares (%) for Therapeutic Proteins by Class, 2003
Figure 4.4 Market Shares (%) in the Global Therapeutic Protein Market by
Company, 2003
Figure 5.1 The Erythropoietin Feedback Loop
Figure 6.1 Protocol for the Production of Monoclonal Antibodies (Anti-Snake
Venom)
Figure 6.2 Global Market Shares (%) for MAb Classes, 2003
Figure 6.3 Global Market Shares (%) for MAbs by Indication, 2003
Figure 11.1 Global Market Shares (%) for the Top Ten Therapeutic Proteins,
2010
Figure 11.2 Global Market Shares (%) for Classes of Therapeutic Protein,
2010
Figure 11.3 Global Market Shares (%) for Categories of Therapeutic Protein,
2010
Figure 11.4 Global Market Shares (%) for the Top Ten Companies in the
Therapeutic Protein Market, 2010


COMPANIES MENTIONED IN THIS REPORT

3M Drug Delivery Systems
Abbott Laboratories
Abgenix
Alfacell
Alkermes Inc.
Altus
Amarillo Biosciences
Amgen
Antisoma
Aphton
Aventis
Bayer
Biocon
Biogen
Biogen Idec.
Biomarin
Biomura
Bioscience Contract Prodcution
Biovex
Boehringer-Ingelheim
Borealis Ventures
Boston Millenia Partners
Cangene
Celltech
Centacor
Chiron
Chugai Phamra
Coremed
Corixa
Covance
CSL
Dendreon
DSM
Eli Lilly
Emisphere Technologies
Epimmune
Fletcher Spaght Ventures
Genencor
Genentech
Generex Biotech
Genzyme
GlaxoSmithKline
GlycoFi
Goodwin Biotechnology
Human Genome Sciences
Idec
ILEX Oncology
ImClone
Immunex
ImmunoGen
Innogenetics
Intarcia
Intercell
Interferon Sciences
InterMune
Janssen-Cilag
Johnson and Johnson
Kirin Brewery Company
Lonza
Lundbeck
Mannkind Corporation
Maxygen
MedImmune
Merck
Nastech Pharmaceutical
NCI
Nobex
Novartis
Novo Nordisk
Ortho Biologics LCC
Ortho Biotech
Par Pharmaceutical
PDL
Peninsula Equity Partners
Pfizer
Pharmacia Corporation
Polaris Ventures
Polymasc Pharmaceuticals
Roche
Sandoz
Sankyo
Sanofi-Aventis
Schering-AG
Schering-Plough
Schroder Ventures Life Sci.
Serono
Shire Pharmaceuticals
SouthWest Oncology Group
Syntonix Pharmaceuticals
Takeda
Tanabe Seiyaku
Tanox
Teva Neuroscience
Teva Pharmaceutical Industries
Therion Biologics
Three Rivers Pharmaceuticals
Titan Pharma
Transkaryotic Therapies
Valentis
Village Ventures
West Drug Delivery
Wyeth
Yamanouchi
YM Biosciences

-PRICING-

Individual report pricing - single user copies of this report are available
for only GBP £1999 (US$3798)
Departmental copies (this entitles up to 5 individual users in your
department) of this report are available for only GBP £2999 (US$5698)
Allow your whole company to have access to this information for only GBP
£4999 (US$9498). Company-wide License allows your whole company access and
intranet use on CD Rom and .pdf. Suitable for library use.

Carriage is via FedEx:
USA - GBP£19.00 ASIA - GBP£25.00 Australia & NZ - GBP£25.00
EU GBP£23.00 Rest of Europe GBP£27.00
UK is sent next day delivery through Royal Mail.

-ORDERING-

Ordering is simple! All you need to do to order this report is contact
Althea James. You can either call me on TEL: +44 (0)208 767 6711 or email:
mailto:althea.james@xxxxxxxxxxxxxxxxxxx

Plus our new virtually round-the-clock customer service means we are
available to assist you with your order even longer. Call us on +44 (0)208
767 6711 between the hours of 9am to 5.30pm GMT Monday to Friday or for
assistance outside of these hours call +1 866 9563001 between the hours of
9am and 5.30 pm PST.

Please feel free to contact me should you have any questions, or wish to
purchase a copy, I look forward to hearing from you.

Kind Regards

Althea James
visiongain
Tel: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Outside European hours please call TEL: +1 866 9563001
e-mail : mailto:althea.james@xxxxxxxxxxxxxxxxxxx

============================================================================
=================================
============================================================================
=================================
Contract Research and Manufacture in the Global Pharmaceutical Industry

The industry for the outsourcing of activities associated with the
development and manufacture of pharmaceutical products has been an arena of
considerable change in recent years.
Companies need to be keenly aware of the importance of the sector.

Available to read in one comprehensive format - you should order this report
immediately. The most comprehensive and detailed Pharmaceutical Outsourcing
report available.

Riding the peaks and troughs of its R&D partners, the 1990s were a time of
great growth for the outsourcing sector, but in a climate of weak pipelines
and uncertain future for "Big Pharma" product candidates, the sector has
been required to reassess its operational strategies.

Competition from overseas markets is also set to have a considerable impact
on this area of the market, with generic pharma companies becoming wise to
the use of cost-effective manufacture and process chemistry overseas - a
factor which is likely to deliver a further blow to contract service
providers in the US and Europe.

For full table of contents please email
mailto:althea.james@xxxxxxxxxxxxxxxxxxx
============================================================================
=================================
============================================================================
=================================
visiongain produce a range of timely business information material, if you
wish to receive information of new products, simply reply to this email with
' New Products info' in the subject box.

By replying to this e-mail submitting your order for this product you have
agreed without limitation or qualification to be bound by and to comply with
these Terms and Conditions. You agree that you will not fail to complete any
transaction after submitting an order to purchase a product or submit any
order to purchase a product where you do not intend to complete the
transaction.You expressly acknowledge and agree that visiongain Ltd can
withhold any product as a result of non-payment within the agreed credit
terms of 30 days. Management Reports will only be sent on receipt of
payment.Confirm any cancellations, prior to payment, in writing within one
week and receive a refund less a 10% + VAT service charge. Regrettably, no
refunds can be made for cancellations after one week.

Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. We may share your data with external
companies offering complimentary products or services. If you wish your
details to be amended, suppressed or not passed onto any external third
party, please send your request to the Database Manager, visiongain Ltd, 40
Tooting High Street, London, SW17 0RG. Please allow approximately 7 days for
your removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.

Should you wish your name to be taken off Visiongain's email list, simply
reply and ask to be unsubscribed.





P0081